Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics From Single Dose of Intramuscular (IM) and Subcutaneous (SC) Donepezil (GB-5001) Injections Versus Donepezil Oral Tablet (Aricept®) in Healthy Male Volunteers

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 3, 2024

Primary Completion Date

September 17, 2024

Study Completion Date

January 14, 2025

Conditions

Alzheimer Disease

Interventions

DRUG

GB-5001A

Depending on the cohort, volume will be varied to administer, and the dosage and route of administration may be varied.

DRUG

GB-5001D

Depending on the cohort, volume will be varied to administer.

DRUG

Oral cohort

Single dose of Aricept tablet.

Trial Locations (1)

RECRUITING

Chungnam National University Hospital, Daejeon

All Listed Sponsors

lead

G2GBio, Inc.

INDUSTRY